Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Active not recruiting × iberdomide × Clear all

Phase

Phase 2 3 Phase 1/2 3 Phase EARLY_PHASE1 1 Phase 3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Radiotherapy 7 Nivolumab 7 pembrolizumab 6 Magnetic Resonance Spectroscopy 6 Temozolomide 3 Specimen Handling 3 Ipilimumab 3 Dexamethasone 3 Biopsy 3 Bevacizumab 3 olaparib 2 niraparib 2 gallium 68 PSMA-11 2 durvalumab 2 avelumab 2 Standard of Care 2 Positron-Emission Tomography 2 Neoadjuvant Therapy 2 Metastasectomy 2 Irinotecan 2 Immunoglobulin G 2 Fluorodeoxyglucose F18 2 FAPI-46 2 Disulfides 2 Cetuximab 2 Abiraterone Acetate 2 68Ga-DKFZ-PSMA-11 2 zimberelimab 1 venetoclax 1 tremelimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05560399 2026-01-02

CC-220

Icahn School of Medicine at Mount Sinai

Phase EARLY_PHASE1 Active not recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡